Vivo Capital LLC reduced its stake in Apellis Pharmaceuticals Inc (NASDAQ:APLS) by 56.1% during the first quarter, HoldingsChannel.com reports. The firm owned 383,538 shares of the company’s stock after selling 491,035 shares during the period. Vivo Capital LLC’s holdings in Apellis Pharmaceuticals were worth $7,479,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in APLS. Hillhouse Capital Advisors Ltd. purchased a new stake in Apellis Pharmaceuticals in the fourth quarter valued at approximately $29,410,000. BlackRock Inc. boosted its holdings in Apellis Pharmaceuticals by 30.8% in the fourth quarter. BlackRock Inc. now owns 3,730,626 shares of the company’s stock worth $49,208,000 after acquiring an additional 877,431 shares in the last quarter. Orbimed Advisors LLC bought a new stake in Apellis Pharmaceuticals in the fourth quarter worth $4,313,000. Assenagon Asset Management S.A. bought a new stake in Apellis Pharmaceuticals in the first quarter worth $6,025,000. Finally, Victory Capital Management Inc. boosted its holdings in Apellis Pharmaceuticals by 21.7% in the first quarter. Victory Capital Management Inc. now owns 1,688,663 shares of the company’s stock worth $32,929,000 after acquiring an additional 300,900 shares in the last quarter. 66.28% of the stock is currently owned by institutional investors and hedge funds.
APLS has been the subject of several recent analyst reports. Zacks Investment Research cut Apellis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, April 30th. Robert W. Baird initiated coverage on Apellis Pharmaceuticals in a research note on Thursday, March 28th. They issued an “outperform” rating and a $45.00 price target for the company. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $52.00 price target on shares of Apellis Pharmaceuticals in a research note on Wednesday, May 8th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Apellis Pharmaceuticals presently has an average rating of “Buy” and an average price target of $41.83.
Apellis Pharmaceuticals stock traded up $1.01 during mid-day trading on Wednesday, reaching $21.50. 4,275 shares of the stock traded hands, compared to its average volume of 425,370. The stock has a market cap of $1.30 billion, a PE ratio of -9.18 and a beta of 0.43. The company has a debt-to-equity ratio of 0.05, a quick ratio of 15.23 and a current ratio of 15.23. Apellis Pharmaceuticals Inc has a 12-month low of $11.45 and a 12-month high of $24.84.
Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.20). As a group, sell-side analysts predict that Apellis Pharmaceuticals Inc will post -3.16 EPS for the current fiscal year.
Apellis Pharmaceuticals Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.
See Also: Bid-Ask Spread
Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals Inc (NASDAQ:APLS).
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.